カテゴリ： GlobalData, 企業調査, 日本

Mitsubishi Tanabe Pharma Corp (4508)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Mitsubishi Tanabe Pharma Corp (4508) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9906
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：161
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe’s major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp (4508) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 22
Venture Financing 22
QurAlis Raises Funds through Seed Financing 22
Ribometrix Raises USD7.5 Million in Seed Financing 23
Forge Therapeutics Raises USD15 million in Series A Financing 24
Rigontec Raises Additional USD16.7 Million in Series A Financing 25
miRagen Therapeutics Raises USD41 Million in Series C Financing 27
Thrasos Therapeutics Raises USD21 Million in Series D Financing 29
NeuroDerm Raises USD16 Million in Venture Financing 31
Covagen Raises US$50.3 Million In Series B Financing 32
F-Star Alpha Raises US$13 Million In Series A Financing 34
Thrasos Therapeutics Raises US$35 Million In Venture Financing 35
Genocea Biosciences Raises US$30 Million In Series C Financing 37
GenKyoTex Raises US$26 Million In Extended Series C Financing 39
Partnerships 41
Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 41
Mitsubishi Tanabe Pharma and Hitachi Enter into Agreement 42
Dyadic International Enters into Research Agreement with Mitsubishi Tanabe Pharma 43
AvantGen Partners with Tanabe Research Laboratories USA 44
Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics Form Partnership 45
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 46
Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 47
Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 48
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 49
Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 51
Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 52
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 53
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 54
Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 55
Medicago Enters into Contract with Public Health Agency of Canada 56
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 57
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 58
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 59
Medicago Enters into Agreement with University of Cape Town 60
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 61
AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 62
Medicago Enters Into Co-Development Agreement With A Global Pharma Company 63
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 64
Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 65
Medicago Enters Into Co-Development Agreement With Cellectis 66
Licensing Agreements 67
Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 67
Mitsubishi Tanabe Pharma to Terminate Licensing Agreement with Kolon Life Science 68
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 69
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 70
AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 71
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 72
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 73
Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 75
Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 76
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 77
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 78
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 80
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 81
Equity Offering 82
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 82
NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 84
NeuroDerm Raises USD77 Million in Public Offering of Shares 86
NeuroDerm Raises USD45 Million in IPO 88
Medicago Announces Private Placement Of Common Stock For US$3.4 Million 90
Asset Transactions 91
Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 91
Acquisition 92
Mitsubishi Tanabe Pharma Acquires Stelic Institute 92
Merck Acquires Rigontec 93
Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 95
Nipro Acquires Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 97
CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 98
Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 99
Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 101
Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 103
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 104
Mitsubishi Tanabe Pharma Corp – Key Competitors 106
Mitsubishi Tanabe Pharma Corp – Key Employees 107
Mitsubishi Tanabe Pharma Corp – Locations And Subsidiaries 108
Head Office 108
Other Locations & Subsidiaries 108
Joint Venture 110
Recent Developments 112
Strategy And Business Planning 112
Sep 29, 2017: Mitsubishi Tanabe Pharma: Organizational Change and Personnel Change 112
Financial Announcements 113
Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 113
May 10, 2017: Mitsubishi Tanabe Pharma Reports Revenue Of JPY424 Billion In Fiscal 2017 115
Corporate Communications 116
Sep 28, 2018: New country manager brings significant business leadership and healthcare expertise to Mitsubishi Tanabe Pharma Canada 116
Government and Public Interest 117
Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 117
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 118
Product News 119
11/30/2017: Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA (edaravone) to U.S. Department of Veterans Affairs National Formulary 119
11/16/2017: Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available 120
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library 121
08/11/2017: Allegheny General Hospital Patient Among First in U.S. to Receive New Drug for Treatment of ALS 122
08/08/2017: First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S. 123
07/25/2017: MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA 124
06/30/2017: MT Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients 125
06/20/2017: Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District Court 126
05/18/2017: MT Pharma America Presents 12-Month RADICAVA (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting 127
05/16/2017: Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS 128
05/05/2017: MT Pharma America Announces FDA Approval of RADICAVA (Edaravone), the First New Treatment Option for ALS in More Than 20 Years 129
04/24/2017: Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS 130
04/18/2018: Mitsubishi Tanabe Pharma America Announces ALS Presentations At American Academy Of Neurology Annual Meeting 132
02/21/2017: Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia 133
Product Approvals 134
May 28, 2018: EMA accepts our filing for Edaravone to treat ALS 134
Apr 10, 2018: Health Canada Accepts Mitsubishi Tanabe Pharma’s NDS Filing for Edaravone to Treat ALS 135
Jan 23, 2018: Swissmedic accepts our filing for Edaravone to treat ALS 136
Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS 137
Clinical Trials 138
Jun 21, 2018: Mitsubishi Tanabe Pharma America to Present Data on RADICAVA (edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting 138
Apr 09, 2018: Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder 139
Dec 19, 2017: Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia 140
Dec 05, 2017: Mitsubishi Tanabe Pharma America to Present Data on RADICAVA (Edaravone) At 28th International Symposium on ALS/MND in Boston 141
Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a 142
Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS 144
Sep 07, 2017: Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal 145
Sep 05, 2017: Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS 146
Jul 31, 2017: American Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia 148
Jun 22, 2017: Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia 149
May 15, 2017: Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA 150
May 15, 2017: Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101 151
Apr 20, 2017: MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting 153
Jan 20, 2017: Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function 154
Other Significant Developments 155
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library 155
Sep 26, 2018: Mitsubishi Tanabe Pharma announce company name changes of our oversea subsidiaries 156
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” 157
Mar 06, 2018: Mitsubishi Tanabe Pharma Announces Singapore Subsidiary Name Change 158
Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma Strengthening business development in the ASEAN region 159
Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region 160
Appendix 161
Methodology 161
About GlobalData 161
Contact Us 161
Disclaimer 161

List of Tables
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Mitsubishi Tanabe Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 12
Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
QurAlis Raises Funds through Seed Financing 22
Ribometrix Raises USD7.5 Million in Seed Financing 23
Forge Therapeutics Raises USD15 million in Series A Financing 24
Rigontec Raises Additional USD16.7 Million in Series A Financing 25
miRagen Therapeutics Raises USD41 Million in Series C Financing 27
Thrasos Therapeutics Raises USD21 Million in Series D Financing 29
NeuroDerm Raises USD16 Million in Venture Financing 31
Covagen Raises US$50.3 Million In Series B Financing 32
F-Star Alpha Raises US$13 Million In Series A Financing 34
Thrasos Therapeutics Raises US$35 Million In Venture Financing 35
Genocea Biosciences Raises US$30 Million In Series C Financing 37
GenKyoTex Raises US$26 Million In Extended Series C Financing 39
Mitsubishi Tanabe Pharma and Osaka University Enter into Agreement 41
Mitsubishi Tanabe Pharma and Hitachi Enter into Agreement 42
Dyadic International Enters into Research Agreement with Mitsubishi Tanabe Pharma 43
AvantGen Partners with Tanabe Research Laboratories USA 44
Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics Form Partnership 45
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 46
Mitsubishi Tanabe Pharma Forms Joint Venture with Research Foundation for Microbial Diseases of Osaka University 47
Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma 48
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 49
Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 51
Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 52
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 53
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 54
Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 55
Medicago Enters into Contract with Public Health Agency of Canada 56
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 57
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 58
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 59
Medicago Enters into Agreement with University of Cape Town 60
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 61
AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 62
Medicago Enters Into Co-Development Agreement With A Global Pharma Company 63
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 64
Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 65
Medicago Enters Into Co-Development Agreement With Cellectis 66
Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 67
Mitsubishi Tanabe Pharma to Terminate Licensing Agreement with Kolon Life Science 68
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 69
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 70
AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 71
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 72
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 73
Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 75
Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 76
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 77
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 78
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 80
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 81
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 82
NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 84
NeuroDerm Raises USD77 Million in Public Offering of Shares 86
NeuroDerm Raises USD45 Million in IPO 88
Medicago Announces Private Placement Of Common Stock For US$3.4 Million 90
Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 91
Mitsubishi Tanabe Pharma Acquires Stelic Institute 92
Merck Acquires Rigontec 93
Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 95
Nipro Acquires Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 97
CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 98
Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 99
Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 101
Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 103
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 104
Mitsubishi Tanabe Pharma Corp, Key Competitors 106
Mitsubishi Tanabe Pharma Corp, Key Employees 107
Mitsubishi Tanabe Pharma Corp, Other Locations 108
Mitsubishi Tanabe Pharma Corp, Subsidiaries 109
Mitsubishi Tanabe Pharma Corp, Joint Venture 110

List of Figures
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 14

★海外企業調査レポート[Mitsubishi Tanabe Pharma Corp (4508)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Strata-X Energy Ltd (SXE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Strata-X Energy Ltd (Strata-X Energy), formerly Strata-X Ltd, is an independent oil and gas exploration company. The company operates in the acquisition, exploration and development of oil and gas properties in the US states of California and Illinois and in the Republic of Botswana. It prov …
  • Masimo Corp (MASI)：医療機器：M&Aディール及び事業提携情報
    Summary Masimo Corp (Masimo) is a medical technology company that develops, manufactures and markets non-invasive patient monitoring technologies, medical devices and sensors to improve patient care. The company’s proprietary technologies include signal extraction technology (SET) that helps detect …
  • Callon Petroleum Co (CPE)：企業の財務・戦略的SWOT分析
    Summary Callon Petroleum Co (CPC) is an oil and gas company that offers building reserves and production of onshore and offshore oil and natural gas. The company carries out acquisition, development, exploration, and exploitation of unconventional onshore, oil, and natural gas reserves. It operates …
  • Ascena Retail Group, Inc.：企業の戦略・SWOT・財務情報
    Ascena Retail Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ascena Retail Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Cohort Plc
    Cohort Plc - Strategy, SWOT and Corporate Finance Report Summary Cohort Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Informa PLC (INF)：企業の財務・戦略的SWOT分析
    Informa PLC (INF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Eurofins MWG Operon LLC-製薬・医療分野：企業M&A・提携分析
    Summary Eurofins MWG Operon LLC (Eurofins) is a biotechnology company that provides DNA sequencing, DNA synthesis and bioinformatic services. The company’s products include DNA tube oligos, large scale synthesis, large scale synthesis, oligo modifications, oligo modifications, real-time QPCR probes, …
  • St. James’S Place Plc
    St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report Summary St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • FitLife Brands Inc：企業の戦略・SWOT・財務情報
    FitLife Brands Inc - Strategy, SWOT and Corporate Finance Report Summary FitLife Brands Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • DSG Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary DSG Inc (DSG) is a provider of eClinical software solutions. The company offers software products such as eCaseLink EDC, eClinDirect CTMS, eCaseLink.Me ePRO, DSG Drug Safety, eCaseLink IRT, DSG Designer, CaseXport, CaseView Imaging, and others. Its services include data management, technolog …
  • Amerisafe Inc：企業の戦略・SWOT・財務分析
    Amerisafe Inc - Strategy, SWOT and Corporate Finance Report Summary Amerisafe Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • StealthGas Inc (GASS)：企業の財務・戦略的SWOT分析
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …
  • Optiscan Imaging Limited (OIL)：製品パイプライン分析
    Summary Optiscan Imaging Limited (Optiscan) is a technology and product development company. It focuses on the development and application of microscopic imaging technologies for medical procedures. The company’s key product is ViewnVivo, a miniaturized fluorescence endo-microscope platform that bri …
  • Australian Pharmaceutical Industries Ltd (API)：企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Robert Half International Inc. (RHI)：企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Archer Ltd (ARCHER)：石油・ガス：M&Aディール及び事業提携情報
    Summary Archer Ltd (Archer) is an oilfield services company. It provides drilling services, well integrity and intervention, plug and abandonment and decommissioning. Its drilling and work-over services include platform drilling, land drilling, modular rigs, drilling fluids, solids control, engineer …
  • Stanmore Coal Ltd：企業の戦略・SWOT・財務分析
    Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report Summary Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Danfoss AS：企業の戦略的SWOT分析
    Danfoss AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • iBio Inc (IBIO)-製薬・医療分野：企業M&A・提携分析
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It uses its ibiolaunch platform, which is a transformative technology for the production of monoclonal antibodies, …
  • SGS SA (SGSN)：企業の財務・戦略的SWOT分析
    SGS SA (SGSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆